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Objective: Dietary L-carnitine can be metabolized by intestinal microbiota to trimethylamine, which is
absorbed by the gut and further oxidized to trimethylamine N-oxide (TMAO) in the liver. TMAO plasma
levels have been associated with atherosclerosis development in ApoE/mice. To better understand the
mechanisms behind this association, we conducted in vitro and in vivo studies looking at the effect of
TMAO on different steps of atherosclerotic disease progression.
Methods: J774 mouse macrophage cells were used to evaluate the effect of TMAO on foam cell formation.
Male ApoE/ mice transfected with human cholesteryl ester transfer protein (hCETP) were fed L-
carnitine and/or methimazole, a ﬂavin monooxygenase 3 (FMO3) inhibitor that prevents the formation of
TMAO. Following 12 week treatment, L-carnitine and TMAO plasma levels, aortic lesion development,
and lipid proﬁles were determined.
Results: TMAO at concentrations up to 10-fold the Cmax reported in humans did not affect in vitro foam
cell formation. In ApoE/mice expressing hCETP, high doses of L-carnitine resulted in a signiﬁcant in-
crease in plasma TMAO levels. Surprisingly, and independently from treatment group, TMAO levels
inversely correlated with aortic lesion size in both aortic root and thoracic aorta. High TMAO levels were
found to signiﬁcantly correlate with smaller aortic lesion area. Plasma lipid and lipoprotein levels did not
change with treatment nor with TMAO levels, suggesting that the observed effects on lesion area were
independent from lipid changes.
Conclusion: These ﬁndings suggest that TMAO slows aortic lesion formation in this mouse model and
may have a protective effect against atherosclerosis development in humans.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular diseases (CVDs) are the major cause of deaths
worldwide [1]. It is estimated that 23.3 million people will die from
heart disease and stroke by 2030 [2]. Atherosclerosis, one of the
leading causes of CVDs is affected by dyslipidemia, genetic back-
ground, environmental factors, stress, inﬂammatory status, low
physical activities, nutrition, diabetes and hypertension [3e6].
Interestingly, recent studies have reported the contribution of gut
microbiota on the progression of atherosclerosis [7e11]., Lonza Inc, 90 Boroline Rd,
Bellamine).
Ireland Ltd. This is an open accessIntestinal microbiota is comprised of more than 100 trillion
typically non-pathogenic commensal microorganisms, and it is
estimated that more than 90% of the DNA in a human body is
actually microbial DNA [12e14]. Intestinal microbiota aids in the
digestion, absorption and metabolism of nutrients [15,16]. How-
ever, more recently, microbiota was reported to contribute to
increased risk of cardiovascular disease, obesity, insulin resistance,
type II diabetes and asthma [17e22].
L-carnitine is a quaternary ammonium compound involved in
the energy metabolism that is produced in liver and kidney from
lysine and methionine or taken up with the diet. It is required for
fatty acid transport to mitochondria and b-oxidation [23]. Clinical
studies suggested a beneﬁcial role of L-carnitine on atherosclerosisarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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controlled trials, including 3629 patients, showed that L-carnitine
supplementation was associated with a 27% reduction in all-cause
mortality, 65% reduction in ventricular arrhythmias and 40%
reduction in the development of angina and infarct size [25].
However, recent clinical studies in humans reported an association
between plasma levels of trimethylamine N-oxide (TMAO), a
metabolite that can be generated from L-carnitine, choline or
betaine, and atherosclerosis development [8,22,26,27]. When not
absorbed by the gut, these precursors can be metabolized to tri-
methylamine (TMA). TMA is then absorbed by the gut into the
circulation and is oxidized by a family of liver ﬂavin-containing
mono-oxygenases (FMO) [28]. The resulting metabolite, TMAO is
then excreted as it is in urea [29]. Recent studies linked TMAO
plasma levels to atherosclerotic disease progression. The cause of
this association, however, is still unclear [7,19,25].
In an attempt to provide a mechanistic explanation for this
association, Koeth and colleagues used a common model of
atherosclerosis, the ApoE/- mouse [8]. Mice were fed large
amounts of L-carnitine (2000 mg/kg/day) resulting in elevated
plasma TMAO levels. TMAO was correlated with increased
atherosclerotic lesion size, possibly resulting from a 35% decrease
in reverse cholesterol transport (RCT) compared to control [8].
Although ApoE/ mice have been used extensively as an athero-
sclerosis model, they lack cholesteryl-ester transfer protein
(CETP), a key enzyme in the RCT, which transfers cholesterol ester
from high density lipoprotein (HDL) to low density lipoprotein
cholesterol (LDL) [30]. In addition, the small numbers of animals
that showed larger aortic lesions (only in four out of 11 animals)
and the lack of doseeresponse (a single TMAO dose has been
assessed) made it difﬁcult to understand the nature of the rela-
tionship between TMAO plasma levels and effects on lesion size
[8]. More recently, the same authors reported that diet-induced g-
butyrobetaine had similar effects on the aortic lesion size [31].
These effects are resolved with antibiotic treatment, which reduce
the conversion of L-carnitine to TMA [8,31].
Several mouse models expressing human CETP have been
developed [32,33], and used to explore CETP inhibition as a thera-
peutic target for atherosclerosis treatment [34,35]. In the current
study, using ApoE/mice expressing hCETP treated with two doses
of L-carnitine and/or methimazole, an inhibitor of FMO, we show for
the ﬁrst time that high TMAO plasma levels were signiﬁcantly
associated with reduced aortic lesion area. Data presented here
strongly suggest that TMAO reduces aortic lesion progression in this
model. The observed effects on lesion size were independent from
plasma lipid and lipoprotein levels. Furthermore, TMAO at concen-
trations 10-fold higher than the reported human plasma maximum
concentration did not affect foam cell formation in mouse macro-
phages in vitro. The potential role of TMAO in the prevention of
atherosclerosis disease progression in humans is discussed.
2. Material and methods
2.1. Cells and reagents
J774 cells and acetylated LDL (AcLDL) were a kind gift from
George Rothblat (Children's Hospital of Philadelphia). L-carnitine
was provided by Lonza Inc. (Allendale, NJ) and methimazole and
TMAO were purchased from SigmaeAldrich (Milwaukee, WI).
2.2. Cholesterol efﬂux assay
Cholesterol efﬂux studies were conducted as previously
described with minor modiﬁcations [36]. Labeling medium
included acetylated LDL (12 or 50 mg/ml) and varying doses ofTMAO (ranging from 0 to 100 mM). Efﬂux media containing 20 mg/
ml human ApoA-I, 20 mg/ml human HDL3 or media alone were
added to untreated cells (-cAMP). In addition, 20 mg/ml human
ApoA-I or medium alone were added to cells treated with cpt-
cAMP. Cellular free cholesterol (FC) and cholesteryl ester (CE)
separated using thin-layer chromatography were quantitated by
liquid scintillation counting. Release of [3H]-cholesterol from cells
during 4 h efﬂux was expressed as a percentage of [3H]-cholesterol
present as FC within cells at time zero. Comparison of cholesterol
efﬂux to ApoA-I from cells both with and without cAMP treatment
was measured to verify the contribution of the ABCA1 cholesterol
efﬂux pathway. All cholesterol efﬂux values are expressed as
average ± standard deviation of triplicate measurements.
2.3. Cholesterol mass assay
Effects of TMAO on cholesterol loading of macrophages were
conducted without radiolabeled cholesterol in parallel with
cholesterol efﬂux assays. Lipids were extracted from cells, and total
cholesterol mass was determined using Cholesterol E kit (Wako
Diagnostics, USA). The fraction of cholesterol mass present as free
cholesterol (FC) and esteriﬁed cholesterol (CE) in cells was calcu-
lated by multiplying the total cholesterol mass by the fraction of
cellular [3H]-cholesterol present as FC and CE. Cellular protein was
determined using Markwell-modiﬁed Lowry assay [37]. All
cholesterol mass determinations (mg/mg cell protein) are expressed
as average ± standard deviation of triplicate measurements.
2.4. Animals
Male ApoE KO mice (ApoE/) purchased from Jackson Labora-
tories (Bar Harbor, ME) were transfected with an adeno-associated
viral vector containing the human CETP gene (AAV2/8-hCETP, ob-
tained from ReGenX Biosciences, Rockville, MD) as described by
Tanigawa et al. [38]. CETP expressionwas veriﬁed at 2 and 14 weeks
following CETP-AAV transfection using a commercially available
ELISA kit from ALPCO Diagnostics (Salem, NH). Two weeks post-
transfection, mice were switched to Western Diet TD.88137 from
Harlan Laboratories (Indianapolis, IN) containing 21% fat (wt/wt)
and 0.15% cholesterol for 12 weeks of treatment. Mice were then
sacriﬁced and tissues removed for analysis. All treatments were
prepared fresh weekly, aliquoted into daily dosing volumes and
stored at20 C. Aliquots were thawed at room temperature for 1 h
prior to dosing. L-carnitine and methimazole were dissolved in
sterile dH2O and administered once daily by oral gavage at speciﬁed
doses based on body weight at a volume of 1 ml per 100 g of body
weight. Blood was collected at 0, 6 and 12 weeks of treatment via
the orbital plexus under isoﬂurane anesthesia (3%). All animals
were weighed weekly to monitor health. Animal housing and
experimental methods were approved by Vascular Strategies
Institutional Animal Care and Use Committee.
2.5. Plasma analysis of L-carnitine and trimethylamine N-oxide
Plasma levels of L-carnitine and trimethylamine N-oxide
(TMAO) in mice were analyzed using liquid chromatography-mass
spectrometry (LC-MS) as previously described by Koeth et al., 2013
[8]. In brief, 50 mL of the mouse plasma samples were pipetted into
a 2 mL centrifuge tube, where 50 mL of HPLC grade acetonitrile and
100 mL of internal standard solution were then added. All samples
were targeted to contain 1 mg/mL synthetic d9 - L-carnitine hy-
drochloride (Sigma Aldrich) and 0.1 mg/mL d9-TMAO (Cambridge
Isotope Laboratories, Tewksbury, MA). The mixture was vortexed
for 2 min, followed by centrifugation. The upper supernatant was
taken for HPLC-MS/MS analysis, using an Agilent 1200 HPLC and
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Phenomenex Synergi 4 mm Polar-RP column (150  4.6 mm, 4 mm,
part No. 00F-4336-E0). All analyses was performed at a column
temperature of 30 ± 1 Cwith a mobile phase of 10mM ammonium
formate and methanol. Detection and quantiﬁcation of L-carnitine
and TMAO levels (ppm) was achieved by ESI-MS/MS operating in
the positive ion mode and the developed method was validated as
per the requirements for the ICH guidelines.
2.6. Lipoprotein plasma proﬁling
Total cholesterol, triglycerides, phospholipids and free choles-
terol in mouse plasma were determined using colorimetric kits
from Wako Diagnostics (Richmond, VA). Cholesterol Ester was
determined by subtraction of free cholesterol from total choles-
terol. HDL-C, LDL-C and VLDL-C were determined by gel electro-
phoresis using SPIFE3000 and Cholesterol-Vis kit from Helena
Laboratories (Beaumont, TX).
2.7. Assessment of atherosclerosis and histochemistry
After 12 weeks of treatment, animals were sacriﬁced and
thoracic aorta isolated, trimmed of fat and ﬁxed in formalin for
48e72 h for en face morphometric analysis. In addition, a small
segment of the ascending aorta with heart attached was reserved
for aortic root analysis. For en face analysis, aortas were laid out,
pinned on black matrix and stained with Sudan IV as described
elsewhere [39]. Images were taken using a Nikon Digital Sight DS-
Fi1 camera connected to a SMZ45T stereoscope (Nikon, Inc, Mel-
ville, NY). Following staining, morphometric analysis was per-
formed using NIS Elements software (Nikon, Inc, Melville, NY) to
determine the lesion area. After en face analysis, lipid was extracted
from aortas using the Bligh and Dyer method [40] and total
cholesterol, free cholesterol and cholesterol ester concentrations
(as mg lipid permg protein) were determined as described above for
cellular cholesterol mass analysis.
For aortic root analysis, the heart with approximately 5 mm of
the ascending aorta was cut away from the aortic arch. The apex of
the heart was removed, and remaining heart with the attached
aortic segment placed in Tissue-Tek OCT (Optimal Cutting Tem-
perature) embedding medium (Sakura Finetek USA, Inc, Torrance,
CA), and frozen in a dry ice/2-methylbutane bath. 10 mm thick
sections were cut from the ascending aorta through the entire
aortic sinus until the ventricular chamber was reached. Sections
were stained with hematoxylin-eosin, and imaged using a Nikon
Digital Sight DS-Fi1 camera connected to an Eclipse 50i microscope.
Lesion areas were quantitated using NIS Elements software (Nikon,
Inc, Melville, NY).
2.8. Statistical analysis
Student's t test analysis performed in MS Excel was used where
appropriate to determine differences between treatments and
vehicle groups for both in vitro and in vivo studies. A p < 0.05 was
considered statistically signiﬁcant. In vitro data are expressed as
means ± standard deviation (SD) of triplicate measurements.
In vivo data are expressed as means ± standard error of the mean
(SEM) of each treatment group.
3. Results
3.1. TMAO effect on foam cell formation
One of the ﬁrst steps in atherosclerosis development is foam
cell formation, characterized by engorgement of arterialmacrophages by oxidized LDL cholesterol [41]. Foam cell formation
initiates development of plaque lesions [42e44]. We evaluated the
effects of TMAO on foam cell formation and cholesterol efﬂux.
Foam cell formationwas assessed bymeasuring cholesterol loading
of mouse macrophages with acLDL in the presence of increasing
concentrations of TMAO (1, 3, 10, 30 and 100 mM). Two different
concentrations of acetylated LDL cholesterol (12 and 50 mg/ml)
have been identiﬁed in the linear range of the receptor response
(data not shown). Fig. 1A shows that total, free and esteriﬁed
cholesterol content of J774macrophages at 12 mg/ml acetylated LDL
were not affected by any of the TMAO concentrations. In parallel,
cholesterol efﬂux from acLDL loaded J774 cells to ApoA-I and HDL3
were also measured with increasing TMAO concentrations. Fig. 1B
shows that cholesterol efﬂux from J774 macrophages using ApoAI
as an acceptor (which assesses the ABCA1-mediated cholesterol
efﬂux) and HDL3 (which accesses passive transport as well as SR-BI
and ABCG1-mediated cholesterol efﬂux) were not affected by
different concentrations of TMAO (10, 30 ad 100 mM). These TMAO
concentrations were not toxic to the cells as assessed by total
protein content (Fig. 1C). No differences were seen in cholesterol
uptake or efﬂux between control and TMAO-treated macrophages,
suggesting that foam cell formation was not affected by TMAO. No
TMAO effect was observed when macrophages were loaded with a
higher concentration of 50 mg/ml acetylated cholesterol (data not
shown).
3.2. In vivo plasma levels of L-carnitine and TMAO
ApoE/ mice expressing hCETP were assigned to 5 different
treatment groups (15 animals per group) according to their total
cholesterol levels and fed a western diet. Treatment conditions
included vehicle, 87mg/kg and 352mg/kg, equivalent to a low and a
high equivalent human dose (500 mg and 2000 mg L-carnitine per
day). In addition, to block formation of TMAO, two additional
treatment groups given methimazole at 15 mg/kg [45], alone or in
combination with 352 mg/kg L-carnitine were included. CETP
expression levels were assessed before the start of the treatment and
at study end, and were found to be stable (55e70 mg/ml, data not
shown). None of the treatments affected the weight of the mice
(Fig. 2A). Plasma L-carnitine and TMAO levels were evaluated. A
signiﬁcant dose dependent increase of L-carnitine for treated mice
compared to the controls was observed (Fig. 2B). Interestingly,
methimazole by itself led to a signiﬁcant decrease in L-carnitine
plasma levels. This may be due to non-speciﬁc inhibition of L-carn-
tine transport in the gut by methimazole [46]. Fig. 2C shows a sig-
niﬁcant increase of plasma TMAO levels upon administration of L-
carnitine at 352 mg/kg. However, the lower dose did not produce a
signiﬁcant change compared to control. As expected, the addition of
methimazole led to decreased TMAO levels, but this decrease did not
reach the control level, suggesting that this dose of methimazole is
not sufﬁcient to completely suppress TMAO formation (Fig. 2C).
3.3. TMAO effect on aortic lesions
After 12 weeks of treatment, animals were sacriﬁced for aortic
lesion assessment. Fig. 3AeE and Supplemental Fig. 1 show results
of lesion analysis for two sites where atherosclerotic lesions
commonly develop in mice, the aortic root and the thoracic aorta
(including the aortic arch, although in humans the abdominal aorta
is the most common). Aortic root analysis (area in mm2) showed a
very small but signiﬁcant decrease in lesion size in the L-carnitine
treated groups compared to control group (Fig. 3A). Surprisingly,
methimazole treatment also led to decreased aortic root lesions.
This may be the result of the anti-oxidant and anti-inﬂammatory
effects reported for methimazole [47,48]. Analysis of lesion area
Fig. 1. Effects of TMAO on macrophage cholesterol loading and efﬂux. A) Total, free, and esteriﬁed cholesterol content was evaluated in J774 mouse macrophage cells treated
with the indicated concentrations of TMAO. Cells were incubated with acetylated LDL (12 mg/ml), and increasing concentrations of TMAO for 24 h. Following treatments, cholesterol
mass (free cholesterol, FC or cholesteryl ester, CE) concentrations (mg/mg cell protein) were determined. B) Cholesterol efﬂux was evaluated using ApoAI and HDL3 as acceptors. J774
cells were treated with the indicated concentrations of TMAO and efﬂux to media containing either 20 mg/ml human apoA-I or20 mg/ml human HDL3, for 4 h was measured. C) The
mean ± SD protein content (mg/well) for each group is also depicted in the table to assess the toxicity of each treatment. TMAO; trimethylamine N-oxide.
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in a signiﬁcant correlation (Fig. 3B). However, when only the high L-
carnitine treatment group (352 mg/kg) is considered compared
to vehicle-treated mice, a signiﬁcant inverse correlation was
observed (Fig. 3C, p ¼ 0.0296). On the other hand, en face
morphometric analysis showed no signiﬁcant differences in
thoracic aorta lesion area among the different treatment groups
(Fig. 3D). However, when thoracic aortic lesion areawas assessed as
a function of TMAO plasma levels (and independently from treat-
ment group) for all mice, a negative correlation was obtainedFig. 2. Plasma levels of L-carnitine and TMAO In vivo. ApoE KO mice were transfected with
to the indicated treatment groups for 12 weeks. A) Mouse body weights for all treatments
were measured following the 12 weeks of treatment. TMAO; trimethylamine N-oxide. The(Fig. 3E, p¼ 0.0561). This correlationwas not signiﬁcant and tended
to have two slopes. One at TMAO concentrations higher than
0.1 ppm and another at levels lower than 0.1 ppm.Whenmice were
divided into different subgroups based on their TMAO levels
(<0.05 ppm, 0.05e0.1 ppm, 0.1e0.2 ppm, and >0.2 ppm), signiﬁ-
cantly lower levels of lesion were found in the elevated TMAO level
groups (>0.05 ppm) compared to the lowest TMAO level
(<0.05 ppm) (p ¼ 0.0148, Fig. 3F). All together, these results show
that high TMAO levels signiﬁcantly correlated with lower lesion
incidence.a CETP-AAV at 7e8 weeks of age prior to drug treatments. Animals were were assigned
were evaluated to monitor overall health. Plasma levels of B) L-carnitine and C) TMAO
coefﬁcient of variation for TMAO production is shown for each treatment group.
Fig. 3. Effect of TMAO production on aortic lesions in vivo. Following 12 weeks of treatment, animals were sacriﬁced for aortic lesion assessments. A) Sections (~5 mm) of the
aortic root were cut, followed by hematoxylin-eosin staining and subsequent Nikon imaging. The lesion area (mm2) for each treatment group was then plotted as the mean ± SD
from 15 animals. B) A correlation analysis for all treatments between TMAO and aortic root lesion area was conducted (n ¼ 74 animals). C) A correlation analysis between L-carnitine
(352 mg/kg)-induced TMAO levels and aortic root lesion area versus vehicle-treated mice was conducted (n ¼ 28 mice). D) Thoracic aortas were isolated, formalin ﬁxed, and stained
with Sudan IV for en face analysis using a Nikon computerized imaging system. The % lesion area in thoracic aortas for each treatment group was then expressed as the mean ± SEM
from 14 animals. E) A correlation analysis between % lesion area in thoracic aorta and TMAO concentration was conducted for all treatment points (n ¼ 73). F) A correlation analysis
between the thoracic aorta % lesion area and very low (<0.05 ppm), low (<0.1 ppm), moderate (0.1e0.2 ppm), and high (>0.2 ppm) TMAO levels was conducted. The results are
expressed as the mean ± SEM from 73 animals. TMAO; trimethylamine N-oxide.
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Lipid mass analysis of extracts from the thoracic aortas of the
treatment mice did not show any differences in lipid content
(Fig. 4A). Moreover, the total, free and esteriﬁed cholesterol, as well
as phospholipids and triglycerides, were assessed at 0, 6 and 12
weeks of treatment (Fig. 4BeF). No signiﬁcant changes in choles-
terol levels across treatments, relative to their controls, were
observed (Fig. 4BeD). Phospholipid and triglyceride levels were not
changed (Fig. 4EeF). No signiﬁcant change in VLDL-C, LDL-C, or
HDL-C among the different treatment groups compared to the
control was observed (Fig. 5AeC). The trend of an increase in HDL-C
in the high dose L-carnitine group compared to the control group is
in agreement with previous reports where L-carnitine treatment
increased HDL-C [49,50]. All together, the data suggest that the
effects of TMAO observed on lesion development are independent
from plasma lipid changes in this mouse model.4. Discussion
L-carnitine was ﬁrst isolated from meat extract over a century
ago by two Russian scientists [51], who named the compound after
the Latin word carnis, meaning meat since it is found mainly in
meat products [52]. Supplementation with L-carnitine has long
been associated with enhanced energy generation by stimulating
fatty acid b-oxidation, decreasing recovery time following muscle
stress, and promoting hematopoiesis [53]. L-carnitine has routinely
been added to infant formula for 30 years, because the endogenous
biosynthesis in infants is too low to meet their requirements. In
addition, L-carnitine has also been linked to cardio-protection due
to its ability to attenuate fatty acid ester buildup and its anti-
oxidant effects [25,54]. However, recent investigation into L-carni-
tine metabolites generated by gut microbiota has challenged the
potential beneﬁt of dietary L-carnitine against cardiovascular dis-
eases. Koeth and colleagues [8,31] demonstrated an obligatory role
Fig. 4. Effects of TMAO on aortic and plasma lipid levels In vivo. A) Aortic lipid content (total cholesterol, TC; free cholesterol, FC; and cholesteryl ester, CE) was measured
following 12 weeks of the indicated treatments. Blood from each animal was collected at 0, 6, and 12 weeks of treatment for plasma lipid analysis: B) Total cholesterol, C) free
cholesterol, D) cholesterol ester, and E) phospholipids were analyzed and expressed as the mean ± SEM from 15 animals. F) Triglycerides were determined using colorimetric kits
from Wako Diagnostics (Richmond, VA). The results are expressed as the mean ± SEM from 15 animals.
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olites from ingested L-carnitine in mammals, which has been
associated with the pathogenesis of atherosclerosis [8,31].
In an attempt to address the direct role of TMAO on athero-
sclerosis and understand the nature of the reported association [8],
we conducted a series of studies assessing two stages of athero-
sclerosis development as described by Libby [43], i) in vitro foam
cell formation and function, and ii) in vivo aortic lesion progression
in relation to plasma TMAO levels. We ﬁrst examined the effect of
TMAO on cholesterol loading and efﬂux from mouse macrophages
(Fig. 1AeB) as indication of foam cell formation and function. Irre-
spective of the dose used, TMAO treatment had no effect on acet-
ylated LDL cholesterol loading or cholesterol efﬂux, indicating forFig. 5. Effects of TMAO on lipoprotein particle distribution and triglycerides In vivo. Blo
LDL-C, and C) HDL-C were determined by gel electrophoresis using SPIFE3000 and Cholestthe ﬁrst time that TMAO does not impact foam cell formation [55].
We then evaluated the plasma levels of TMAO in ApoE/ mice
expressing hCETP following 12 weeks of treatment with high
(352 mg/kg) or low (87 mg/kg) L-carnitine administered by oral
gavage, in the presence or absence of the FMO inhibitor methi-
mazole. If TMAO was causative in lesion progression, suppressing
formation of TMAOwith methimazole in mice should reduce aortic
lesion size, whereas no change compared to high L-carnitine
treatment would be expected if atherosclerosis was independent of
TMAO. Conversely, if TMAO was preventative, suppression with
methimazole would result in increased lesion size. Both the high
and low dose of L-carnitine used in this study was sufﬁcient to in-
crease its plasma levels, but only the high dose led to a signiﬁcantod was collected at 0, 6, and 12 weeks of treatment. Plasma lipoproteins A) VLDL-C, B)
erol-Vis kit. The results are expressed as the mean ± SEM from 15 animals.
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L-carnitine did not increase plasma TMAO, possibly because the
Western diet itself contains signiﬁcant amounts of L-carnitine.
Interestingly, methimazole, which inhibits the conversion of TMA
toTMAO, also reduced the plasma levels of L-carnitine (Fig. 2B). This
effect may be the result of non-speciﬁc inhibition of L-carnitine
transport in the gut, mediated by OCTN1/2, a family of transporters
shown to be inhibited by methimazole in human hepatic cells [46].
Increased plasma TMAO levels with high dose L-carnitine was
partially attenuated by methimazole (Fig. 2B). The difference in
response to the two L-carnitine doses and the resulting TMAO
plasma levels may be the result of variations in the gut microbiota
between the individual mice, as reﬂected in the variance (CV %
changes, Fig 2C) shown between treatment groups. Gut microbiota
plays a major role in L-carnitine metabolism in the digestive tract,
and may be rate limiting in TMAO production. Indeed, we didn't
observe an association between TMAO levels and thoracic lesion
areawithin each treatment group compared to the control (Fig. 3B).
But when the TMAO levels were considered independently from
the treatments, a signiﬁcant reduction of aortic lesion formation at
high TMAO levels (>0.05 ppm) was observed. These results indicate
that TMAO may play a protective role in aortic lesion formation
(Fig. 3). Since TMAO did not affect the two ﬁrst steps in athero-
sclerotic disease progression (endothelial cell dysfunction based on
Koeth et al., 2013 and foam cell formation based on this study), it is
possible that during disease progression, up-regulation of TMAO
may modulate lesion development. TMAO has been reported to
function as a chemical chaperone [56,57], possibly facilitating
protein folding and tissue remodeling, a step required in the lesion
regression. In addition, TMAO has been reported to mitigate stress
and reduce apoptosis in epithelial cells challenged with abnormal
protein aggregation [58]. Thus, the potential increase in TMAO as a
result of L-carnitine supplementation may be a compensatory
mechanism to slow lesion progression, rather than the cause on
increased lesions as previously reported [8,31].
Given the difference in atherosclerotic lesion development in
response to L-carnitine between that reported by Koeth [8] and the
present study, it is important to note several differences in how the
studies were conducted. There is a signiﬁcant difference in the di-
etary composition between the two studies. The current study uses
doses of L-carnitine (87 or 352 mg/kg) that are in the range used as
dietary supplements and an atherogenic diet to assess lesion
development. Whereas Koeth [8] used an L-carnitine dose much
higher, approximately 1700 mg/kg/day based on average mouse
consumption of 1.3% L-carnitine as part of a normal chow diet. The
difference in normal chow vs atherogenic diet alone can be seen in
the level of aortic root lesion. Koeth observed lesion sizes of
1e5  105 mm2, which is low level of lesion development. The
current study shows lesion sizes of 0.6e1  107 mm2, a more
advanced stage of lesion development. While both studies used
apoE knockout mice, Koeth used female mice [8] and the current
study uses male mice that express human CETP. For the current
study, a model with CETP expression was chosen because it plays a
signiﬁcant role in reverse cholesterol transport and atherosclerosis
progression and is more relevant to the human disease develop-
ment. Furthermore, in the Koeth study, increased lesions above the
baseline were observed only in 3 out of 11 animals, making the
difference signiﬁcant. It is worthy to note that no doseeresponse
was evaluated [8]. Male mice were chosen in our study because
they are commonly used as an atherosclerotic model and to avoid
variability and high expression levels of FMO isoforms reported in
females [59]. FMO isoforms have been shown to be regulated by
hormonal factors, leading to much higher TMAO plasma levels in
females vs males (about 10-fold higher) [60], making it harder to
detect potential effects of TMAO and inhibition of TMAO bymethimazole more challenging. Indeed, using the male ApoE/
model which have lower plasma levels of TMAO and the maximum
non-toxic dose of methimazole, TMAO decrease was only partially
achieved. By the same virtue, it would be challenging to see sig-
niﬁcant increases in TMAO levels following L-carnitine supple-
mentation if the basal levels of TMAOwere already elevated as seen
in female mice.
Koeth and colleagues reported that the lesion development was
resolved by antibiotic addition [8]. It is possible that this effect can
be the result of the antibiotic effect on the lesions themselves.
Various antibiotics, including doxycycline, have been reported to
reduce inﬂammatory markers in ApoE/ mice that contribute to
atherosclerosis [61,62] and thereby may confound the interpreta-
tion of the Koeth et al. data on the TMAO effects only. It is possible
that the up-regulation of TMAO took place after the lesion forma-
tion started in these animals. When several TMAO plasma levels
were considered and correlated to the lesion occurrence (present
study), a signiﬁcant inverse correlation with the lesion size was
observed (Fig. 3F). In addition, our ﬁndings agree with previous
reports showing that clinically relevant doses of L-carnitine atten-
uated the progression of atherosclerotic lesions in rabbits [63]. Also,
it has been reported that loss of function mutations in the FMO
gene, involved in the formation of TMAO, lead to increased risk of
ischemic stroke among hypertensive individuals [64]. A recent
study by Fukami and colleagues done in 31 hemodialysis patients
conﬁrmed that L-carnitine supplementation (900 mg/d for 6
months) resulted in increased TMA and TMAO levels, but decreased
markers of vascular injury and oxidative stress. Hemodialysis pa-
tients typically have lower than normal plasma L-carnitine levels,
which has been related to accelerated atherosclerosis [65].
L-carnitine has been shown to reduce cholesterol and tri-
glycerides, as well as increase high density lipoproteins (HDL) [23].
To that end, we explored whether L-carnitine or its metabolite,
TMAO, could modulate cholesterol and lipoprotein levels in ApoE/
 mice expressing hCETP, and potentially to affect atherosclerosis
development in this model. Our results showed no signiﬁcant
changes in aortic or plasma cholesterol and triglyceride levels
(Fig. 4), or distribution of cholesterol between themajor lipoprotein
classes (VLDL-C, LDL-C, and HDL-C, Fig. 5) between treated mice
and controls at 0, 6, and 12 weeks of treatment. It should be noted
that, irrespective of treatment received, decreases in total choles-
terol, cholesterol ester, LDL-C, VLDL-C and triglyceride were
observed between 6 and 12 weeks of treatments. The observed
lipid changes may be due to altered response to theWestern diet in
mice expressing CETP. Taken together, these data suggest a poten-
tial role for TMAO in reduced thoracic and aortic root lesion
development and atherosclerosis prevention, an effect indepen-
dent from plasma lipid changes.
In conclusion, the link between gut microbiota metabolism and
CVD risk is fairly recent, and has generated much debate over the
utility of supplemental intake of L-carnitine or meat intake. Our
studies support the previously reported association between TMAO
plasma levels and lesion formation and further clarify the nature of
this association. Indeed, TMAO may likely provide a protective and
not a causative effect on atherosclerosis development.
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